Pargyline

Pargyline

SCHEMBL121111

C#CCN(C)Cc1ccccc1.Cl

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

MAOAMAOB

The experimentally established mechanism targets of Pargyline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAOB known ✓ P27338 2/20 0.96
MAOA known ✓ P21397 1/20 0.96
LMNA P02545 2/20 1.00
ALDH1A1 P00352 1/20 1.00
BLM P54132 1/20 1.00
SMN1; SMN2 Q16637 1/20 1.00
PYCR1 P32322 18/20 0.96
USP2 O75604 1/20 0.96
CYP3A4 P08684 1/20 0.96
TSHR P16473 1/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pargyline SCHEMBL2045 0.98 PYCR1 (1.00) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Pargyline SCHEMBL18036659 0.98 PYCR1 (1.00) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Pargyline SCHEMBL7363311 0.96 PYCR1 (0.96) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Pargyline SCHEMBL2657939 0.91 PYCR1 (0.86) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Pargyline SCHEMBL4441967 0.85 PYCR1 (0.75) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Pargyline SCHEMBL5981667 0.85 PYCR1 (0.75) LMNAALDH1A1BLMSMN1; SMN2PYCR1
SCHEMBL11896612 0.83 PYCR1 (0.72) LMNAALDH1A1BLMSMN1; SMN2PYCR1
SCHEMBL10033796 0.82 PYCR1 (0.71) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Hydrochloric Acid SCHEMBL28077090 0.81 LMNA (0.68) LMNAALDH1A1BLMSMN1; SMN2PYCR1
Dibemethine SCHEMBL2139708 0.80 ALDH1A1 (0.67) LMNAALDH1A1BLMSMN1; SMN2PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2037 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119185270-A Application of pargyline hydrochloride, metadoxine and dimethyl fumarate compound in preparation of product for inhibiting SpCas9 from binding to or cutting off substrate 中国人民解放军空军军医大学 2024-12-27 CN claimed
US-20240245702-A1 Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells MASSACHUSETTS EYE AND EAR INFIRMARY 2024-07-25 US claimed
WO-2024028324-A1 MOLECULES FOR THE PREVENTION AND TREATMENT OF NEUROMUSCULAR DISORDERS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 2024-02-08 WO claimed
US-20230003721-A1 MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-01-05 US claimed
CN-114432498-B Bone repair material and preparation method and application thereof 北京大学口腔医学院 2022-09-23 CN claimed
CN-114432498-A Bone repair material and preparation method and application thereof 北京大学口腔医学院 2022-05-06 CN claimed
US-20220008433-A1 Inhibition of Lysine Demethylase 1 (Lsd1) Induces Differentiation of Hair Cells MASSACHUSETTS EYE AND EAR INFIRMARY 2022-01-13 US claimed
WO-2020213939-A1 PHARMACEUTICAL COMPOSITION FOR CO-ADMINISTRATION OF ANTICANCER DRUG 주식회사 진센 2020-10-22 WO claimed
WO-2020213938-A1 PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING SAPONIN AS ACTIVE INGREDIENT 주식회사 진센 2020-10-22 WO claimed
WO-2020112883-A1 INHIBITION OF LYSINE DEMETHYLASE 1 (LSD1) INDUCES DIFFERENTIATION OF HAIR CELLS MASSACHUSETTS EYE AND EAR INFIRMARY (US) 2020-06-04 WO claimed
EP-0400974-A2 Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists MERCK & CO. INC. (US) 1990-12-05 EP claimed
US-4634716-A ANGIOTENSIN CONVERTING ENZYME INHIBITORS MERCK & CO., INC. (US) 1987-01-06 US claimed
EP-0079522-B1 N-CARBOXYMETHYL(AMIDINO)LYSYL-PROLINE ANTIHYPERTENSIVE AGENTS MERCK & CO. INC. (US) 1986-05-07 EP claimed
US-4584294-A Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents MERCK & CO., INC. (US) 1986-04-22 US claimed
EP-0166353-A2 Benzofused lactams useful as antihypertensive agents and as cholecystokinin antagonists MERCK & CO. INC. (US) 1986-01-02 EP claimed
US-4555503-A ANGIOTENSIN INHIBITORS MERCK & CO., INC. (US) 1985-11-26 US claimed
US-4472380-A CARBOXYALKYL DIPEPTIDE DERIVATIVES MERCK & CO., INC. (US) 1984-09-18 US claimed
EP-0107095-A1 1-N-alkylcarboxy-benzofused lactams useful as antihypertensive agents MERCK & CO. INC. (US) 1984-05-02 EP claimed
EP-0081094-A1 Substituted omega-amino-carboxymethyldipeptide antihypertensive agents MERCK & CO. INC. (US) 1983-06-15 EP claimed
EP-0079522-A1 N-Carboxymethyl(amidino)lysyl-proline antihypertensive agents MERCK & CO. INC. (US) 1983-05-25 EP claimed